LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

Stryker to announce financial results for its first quarter of fiscal year 2023

March 30, 2023 | Last Trade: US$369.59 6.34 -1.69

Kalamazoo, Michigan, March 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2023 on Monday, May 1, 2023.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s first quarter of fiscal year 2023, which ends on Friday, March 31, 2023.

 Stryker will host a webcast at 4:30pm ET on Monday, May 1, 2023, to discuss results for its first quarter fiscal year 2023.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after the live call ends.

About Stryker

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it. 

For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page